Daiichi Sankyo (第一三共株式会社) is a developer of pharmaceutical products. It engages in 4 businesses: the Innovative Pharmaceutical Business, the Generic Business, the Vaccine business, and the OTC-related business. The Innovative Pharmaceutical Business delivers a range of pharmaceuticals to patients ranging from the anticoagulant LIXIANA and other products in the primary care area to oncology products, among others, in the specialty care area. The Generic Business offers authorized generics (AG), or a new standard for generics featuring formulation, labelling, and packaging innovations that are easy to swallow but hard to swallow accidentally. The Vaccine business specializes in vaccines to prevent infectious diseases and develops a 3-valent combination vaccine containing three live attenuated viruses of measles, mumps, and rubella (MMR vaccine). The OTC-related business offers OTC drugs and a range of products including skincare cosmetics and oral care products.